DW1807

DW1807 is a Daewon Pharm fixed-dose combination modified drug candidate being evaluated for perennial allergic rhinitis in adults with comorbid asthma. A randomized, double-blind, active-controlled Phase 3 study compares DW1807 with DW1807-R2 over four weeks, with improvement in reflective total nasal symptom score as the primary efficacy objective. Public trial materials do not disclose DW1807's active ingredients, molecular targets, dosage form, route, or detailed mechanism of action. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168473))

Other names

levodropropizine + bromhexinelevodropropizine/bromhexine combination